Greenlight Capital Re, Ltd. (GLRE), a Bermuda-based reinsurance company backed by David Einhorn’s Greenlight Capital hedge fund, has been a rollercoaster ride for investors over the past decade. Specializing in property and casualty reinsurance, GLRE writes policies that help insurers offload risk, but it’s highly sensitive to catastrophic events like hurricanes. After weathering massive losses from 2017’s devastating hurricanes (Irma and Maria) and other perils, the company has staged a solid recovery, with improving profitability and a rock-solid balance sheet. As of early 2026, the stock trades at levels that scream value to patient investors, especially with recent insider buying and a unanimous analyst thumbs-up for significant upside. Let’s break down the numbers and what they mean for everyday shareholders.
A Bumpy Road: Revenue and Earnings Through the Cycles
GLRE’s revenue tells a story of volatility tied directly to insurance cycles and mother nature. Starting strong in 2016 at $588 million, it peaked at $646 million in 2017 before plummeting 72% to $183 million in 2018 amid catastrophe claims that obliterated earnings—net income swung from a $44 million loss in 2017 to a staggering $354 million loss the next year (a -900% deterioration). This wasn’t just bad luck; it highlighted the reinsurance model’s razor-thin margins, where gross margins cratered to -178% in 2018, underscoring how claims can wipe out years of underwriting discipline.
Fast forward to recovery mode: Revenue rebounded sharply, climbing 194% from 2018 to $538 million in 2019, then stabilizing around $484-$696 million through 2024, with a 4% uptick from 2023’s $667 million to 2024. Revenue per share mirrors this, rising from a low of $5.09 in 2018 to $20.41 in 2024—a 301% increase over six years, signaling steady premium growth as the company rebuilt its book. Earnings per share (EPS) followed suit: after the -9.74 abyss in 2018, it turned positive and climbed to $2.55 in 2023 before dipping 51% to $1.26 in 2024. Why care about EPS? It’s the bottom-line profit per slice of the company you own, and GLRE’s trajectory shows management clawing back profitability, with EBT margins expanding from negative territory to a healthy 13% in 2023 (down to 6.3% in 2024).
Stock price action correlated tightly with these swings. Highs hit $24.10 in both 2016 and 2017 on peak revenues, but lows plunged to $5.00 in 2020 amid COVID-related uncertainties and lingering cat losses— a 79% drop from prior peaks. By 2024, the range firmed up to $10.95-$15.82, roughly tripling from 2020 lows as fundamentals healed. This lag in price recovery versus book value growth (which steadily rose 41% from $13.29 in 2018 to $18.65 in 2024) suggests the market has been slow to reward GLRE’s progress, trading at a discount to intrinsic value.
Balance Sheet Strength: The Safety Net Investors Love
One of GLRE’s standout features is its fortress-like balance sheet, a critical buffer in reinsurance where claims can hit like tsunamis. Shareholders’ equity ballooned 33% from $477 million in 2018 to $636 million in 2024, while total debt shrank 40% from $101 million to $60 million over the same stretch post-2018. This left net debt deeply negative at -$588 million in 2024 (meaning cash hoard exceeds borrowings by that margin), providing ample liquidity for claims or growth. Book value per share, a key metric for insurers as it reflects “net worth” per share after liabilities, grew 40% from $13.29 to $18.65 over six years—steady compounding that outpaced share count shrinkage (down 5% to 34.1 million shares).
Return on equity (ROE) brings this home: from a disastrous -53% in 2018, it flipped to 15.8% in 2023 (the highest in the dataset) before settling at 7% in 2024. ROE measures how efficiently management turns equity into profits—anything above 10-15% is solid for insurers, so GLRE’s rebound signals better capital deployment. Paired with ROA at 2.3% in 2024 (up from negative), it shows assets are generating returns without excessive leverage.
Cash flows add color: Free cash flow per share turned positive at $0.22 in 2023 and surged to $3.24 in 2024 (1,373% jump), fueled by $111 million in operating cash flow. Minimal capex ($1 million in 2024) keeps FCF near operating cash, ideal for a capital-light reinsurer. Compare this to the stock’s price range: as FCF improved, highs climbed from $8.56 in 2022 to $15.82 in 2024, hinting at growing investor confidence.
Operational Efficiency and Growth Signals
Employee count doubled from 35 in 2016 to 75 in 2024 (+114%), but revenue per employee dipped 45% to $9.28 million, suggesting investments in talent for underwriting expansion rather than bloat. Gross margins stabilized around 12-20% post-2019 (versus -178% disaster), reflecting tighter risk selection. No projections for 2025-2027 in the data, but trends point to continued revenue growth if catastrophe losses stay mild—analysts implicitly bet on this with their targets.
A notable event: In 2020, amid pandemic market chaos, GLRE navigated COVID without major underwriting hits, unlike some peers, helping stabilize at $484 million revenue (down just 10% from 2019). More recently, 2023’s banner $87 million net income likely rode favorable pricing cycles in reinsurance, but 2024’s halving reflects normalized claims—still profitable territory.
Valuation: Cheap on Multiple Fronts
At 2024 levels, GLRE’s PE ratio of 11.3x is reasonable for a recovering insurer (down from 48x in 2020), while the lowly 4.4x in 2023 screamed bargain. PS ratio at 0.69x and PB at 0.75x both hover near historic lows, meaning you’re buying $1 of sales or book for under 70-80 cents. Negative EV/Sales (-0.16x) due to net cash makes it even more attractive—enterprise value ignores the cash pile, painting GLRE as undervalued. EV/FCF flipped positive, reinforcing FCF momentum. Historically, as PB dipped below 0.6x in tough years, stock lows followed; now at 0.75x with rising book value, there’s asymmetry to the upside.
Insider Moves: A Bullish November Signal
Insider activity in 2025 paints a mixed but net-positive picture. Sells dominated early—six in March (including Head of Innovations dumping 21,799 shares), one COO sale in May (20,000 shares), and sporadic director/CUO sales through September/November, totaling about $990k in proceeds. These look like routine profit-taking or option exercises (many at $0 cost basis), common in exec comp.
But November flipped the script: three buys totaling $767k, including a hefty 50,000-share purchase by the CEO (at around current levels) and two directors grabbing 5,000 shares each. Insiders putting skin in the game late 2025, post some sells, correlates with stock stabilization into early 2026—often a precursor to outperformance, as leaders buy when they see value.
Analyst Targets and Future Outlook
Analysts are aligned: high, mean, and low price targets all point to roughly 49% upside from the early February 2026 close. This consensus reflects optimism on sustained revenue growth (projected steady in recent years), margin expansion, and cat-light years ahead. Without explicit 2025-2027 fundamentals, we extrapolate: if EPS holds $1.26+ and book value compounds at 5-7% annually (its post-2018 pace), ROE could rebound toward 10%, justifying re-rating higher.
Risks linger—another 2017-style cat season could dent margins—but GLRE’s $930 million working capital and shrinking debt provide a moat. With FCF gushing, potential for buybacks or special dividends adds tailwind. For retail investors, this is classic value: beaten-down insurer with insider buys, cash-rich balance sheet, and 49% analyst upside. If history rhymes, stock highs could revisit $20+ as fundamentals catch up. Keep an eye on 2026 cat activity, but at current multiples, the margin of safety is compelling—worth a position for the long haul.
(Word count: 1,128)